Physician profile
Pritpaul Singh
NPI 1164717807
$857.99
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $305 · 2021: $110.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $450.10 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $141.92 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.69 | 2021 | |
| Sunovion Pharmaceuticals INC. | $62.48 | 2019 | |
| Novo Nordisk INC | $39.81 | 2019 | |
| Abbvie INC. | $39.11 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $26.42 | 2019 | |
| Shire North American Group INC | $13.93 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pritpaul Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.